78281-72-8

78281-72-8 structure

Name: Nepafenac
Chemical Name: nepafenac
CAS Number: 78281-72-8
Molecular Formula: C₁₅H₁₄N₂O₂
Molecular Weight: 254.284
Catalog: Biochemical Inhibitor Neuronal Signaling COX inhibitor
Create Date: 2018-03-02 08:00:00
Modify Date: 2026-07-03 08:57:35
Nepafenac(AHR 9434; AL 6515; Nevanac) is a selective COX-2 inhibitor; is prodrug of Amfenac.IC50 value:Target: COX-2Nepafenac is a NSAID (nonsteroidal anti inflammatory drug) that is routinely used in opthamology to control pain following cataract surgery.

Name	nepafenac
Synonyms	Nafenac - WS Nafenac //BP Nafenac, 10 mM in DMSO 2-(2-amino-3-benzoyl-phenyl)acetamide Nafenac AHR 9434 nafenac,Nevance Nafenac API Nepafanac 2-Amino-3-benzoylbenzeneacetamide NafenacQ: What is Nafenac Q: What is the CAS Number of Nafenac Q: What is the storage condition of Nafenac Q: What e the applications of Nafenac Nevanac 2-(2-Amino-3-benzoylphenyl)acetamide Nafenac> 2-[2-amino-3-(phénylcarbonyl)phényl]acétamide 2-[2-Amino-3-(phenylcarbonyl)phenyl]acetamid NAFENAC STD 2-Amino-3-benzoyl-phenylacetamide Nafenac/AHR9434/AL6515/Nevanac Nafenac a selective COX-2 inhibitor Nafenac (AHR9434 Nafanac AL 6515 (R)-(but-3-yn-2-yloxy)trimethylsilane Benzeneacetamide, 2-amino-3-benzoyl 2-[2-amino-3-(phenylcarbonyl)phenyl]acetamide

Description	Nepafenac(AHR 9434; AL 6515; Nevanac) is a selective COX-2 inhibitor; is prodrug of Amfenac.IC50 value:Target: COX-2Nepafenac is a NSAID (nonsteroidal anti inflammatory drug) that is routinely used in opthamology to control pain following cataract surgery.
Related Catalog	Research Areas >> Inflammation/Immunology
Target	COX-1:64.3 μM (IC50) COX-2
References	[1]. Gamache DA, Graff G, Brady MT et al. Nepafenac, a unique nonsteroidal prodrug with potential utility in the treatment of trauma-induced ocular inflammation: I. Assessment of anti-inflammatory efficacy. Inflammation. 2000 Aug;24(4):357-70. [2]. Ke TL, Graff G, Spellman JM, Yanni JM. Nepafenac, a unique nonsteroidal prodrug with potential utility in the treatment of trauma-induced ocular inflammation: II. In vitro bioactivation and permeation of external ocular barriers. Inflammation. 2000 Aug;24(4):371-84. [3]. Lindstrom R, Kim T. Ocular permeation and inhibition of retinal inflammation: an examination of data and expert opinion on the clinical utility of nepafenac. Curr Med Res Opin. 2006 Feb;22(2):397-404. [4]. Marshall JC, Fernandes BF, Di Cesare S et al. The use of a cyclooxygenase-2 inhibitor (Nepafenac) in an ocular and metastatic animal model of uveal melanoma. Carcinogenesis. 2007 Sep;28(9):2053-8. [5]. Singh R, Alpern L, Jaffe GJ et al. Evaluation of nepafenac in prevention of macular edema following cataract surgery in patients with diabetic retinopathy. Clin Ophthalmol. 2012;6:1259-69.

78281-61-5

~84%

78281-72-8

Literature: Medichem, S.A. Patent: US2009/312575 A1, 2009 ; Location in patent: Page/Page column 5-6 ;

2835-77-0

78281-72-8

Literature: Journal of Medicinal Chemistry, , vol. 33, # 8 p. 2296 - 2304

173262-94-7

78281-72-8

Literature: US5475034 A1, ;

Precursor 2
78281-61-5 2835-77-0
DownStream 0

HS Code	2924299090
Summary	2924299090. other cyclic amides (including cyclic carbamates) and their derivatives; salts thereof. VAT:17.0%. Tax rebate rate:13.0%. . MFN tariff:6.5%. General tariff:30.0%